Prostate Cell News Volume 5.33 | Sep 5 2014

Prostate Cancer Cell-Stromal Cell Crosstalk via FGFR1 Mediates Antitumor Activity of Dovitinib in Bone Metastases
The authors suggest that fibroblast growth factor (FGF) signaling mediates a positive feedback loop between prostate cancer (PCa) cells and bone cells and that blockade of FGF receptor 1 (FGFR1) in osteoblasts partially mediates the antitumor activity of dovitinib by improving bone quality and by blocking PCa cell-bone cell interaction. [Sci Transl Med] Abstract

Targeting Btk/Etk of Prostate Cancer Cells by a Novel Dual Inhibitor
Scientists found that Btk is overexpressed in prostate cancer tissues and prostate cancer cells. The level of Btk in prostate cancer tissues correlates with cancer grades. Knockdown of Btk expression selectively inhibits the growth of prostate cancer cells, but not that of the normal prostate epithelial cells, which express very little Btk. [Cell Death Dis] Full Article

c-Jun NH2-Terminal Kinase-Induced Proteasomal Degradation of c-FLIP_L/S and Bcl₂ Sensitize Prostate Cancer Cells to Fas- and Mitochondria-Mediated Apoptosis by Tetrandrine
Researchers demonstrate that tetrandrine selectively inhibits the growth of prostate cancer PC3 and DU145 cells compared to normal prostate epithelial PWR-1E cells. [Biochem Pharmacol] Abstract

The Pluripotency Factor Nanog Is Directly Upregulated by the Androgen Receptor in Prostate Cancer Cells
Nanog has been previously shown to increase the self-renewal and stem-like properties of prostate cancer cells. Thus, scientists hypothesized that Nanog is a candidate androgen receptor target gene that may impart castration-resistance. [Prostate] Abstract

Vitamin D₃ Regulates the Formation and Degradation of Gap Junctions in Androgen-Responsive Human Prostate Cancer Cells
Scientists investigated the effect of vitamin D₃ on the formation and degradation of gap junctions in an androgen-responsive prostate cancer cell line, LNCaP, which expresses retrovirally-introduced connexin32. [PLoS One]
Full Article

Lectin-Like Oxidized LDL Receptor-1 Is an Enhancer of Tumor Angiogenesis in Human Prostate Cancer Cells
Scientists analyzed the contribution of oxidized low-density lipoprotein (oxLDL) and lectin-like oxidized low-density lipoprotein receptor-1 to tumor angiogenesis using C4-2 prostate cancer cells. [PLoS One] Full Article

CCL2 Promotes Integrin-Mediated Adhesion of Prostate Cancer Cells In Vitro
Since chemokine ligand 2 (CCL2) is significantly up-regulated in patients with prostate cancer, scientists assessed whether CCL2 contributes to invasive behavior of prostate cancer cells in vitro. [World J Urol] Abstract

In Vitro Modeling of HER2-Targeting Therapy in Disseminated Prostate Cancer
A panel of prostate cancer cell lines was subjected to a eight-week treatment using drugs influencing the receptors of tyrosine kinase: trastuzumab, 17-DMAG, alone or in combination, and their HER2 and EGFR expressions were compared with non-treated cells. [Int J Oncol] Abstract

Knockdown of NOB1 Expression Inhibits the Malignant Transformation of Human Prostate Cancer Cells
Knockdown of nin one binding-1 protein (NOB1) by lentivirus-shRNA inhibited the proliferation and colony-formation ability of PC-3 and DU145 prostate cancer cells. [Mol Cell Biochem] Abstract

CLINICAL RESEARCH

AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Researchers hypothesized that detection of androgen-receptor splice variant 7 messenger RNA (AR-V7) in circulating tumor cells from men with advanced prostate cancer would be associated with resistance to enzalutamide and abiraterone. [N Engl J Med] Abstract

Clinical Activity of Enzalutamide in Docetaxel-Naïve and Docetaxel-Pretreated Patients with Metastatic Castration-Resistant Prostate Cancer
Scientists examined the impact of prior D treatment on the clinical activity of enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC). They retrospectively reviewed an institutional database to identify men with mCRPC treated with standard-of-care enzalutamide. [Prostate] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

Sophiris Bio Reports Completion of Enrollment in the “PLUS-1” Phase III Trial of PRX302 for Benign Prostatic Hyperplasia
Sophiris Bio Inc., a biopharmaceutical company developing PRX302 (topsalysin) for the treatment of the symptoms of benign prostatic hyperplasia (BPH) and for the treatment of localized prostate cancer, announced that it has fully enrolled its ongoing Phase III trial of PRX302 as a treatment for lower urinary tract symptoms of BPH. [Sophiris Bio Inc.] Press Release

New wallchart from our sponsor:
Mesenchymal Stem Cells (a Nature Reviews Molecular Cell Biology collaboration). Request your free copy.

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the prostate cell community.

NEW Postdoctoral Position – Prostate Cancer Research (Umeå University)

NEW Tenure Track Position – Prostate/Bladder Cancer (National Cancer Institute)

NEW Postdoctoral Positions – Prostate Metastasis Evolution (Cold Spring Harbor Laboratory)

Postdoctoral Fellowship Position – Cancer Immunology (Cornell University)

Bioinformatics Analyst / Computational Biologist – Molecular Analysis of Prostate Cancer (Cornell University)

Postdoctoral Fellow – Prostate Cancer (Cleveland Clinic)

Postdoctoral Position – Molecular Physiology in Prostate Cancer (Duke Molecular Physiology Institute)

Postdoctoral Position – Cancer Biology/Genomics (Cornell University)

Scientist – Prostate Cell Research (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.